Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 21Genitourinary 7Breast 5NET 4Endocrine 4Other 3Gynecologic 3Thoracic 2Sarcoma 2Plasma cell 2Dermatologic 2Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Classical hematology 1CNS 1

Conditions

Brain Neoplasms 1905Glioblastoma 1797Glioma 1130Central Nervous System Neoplasms 599Astrocytoma 594Neuroblastoma 552Gliosarcoma 465Oligodendroglioma 364Neoplasms 312Breast Neoplasms 273Medulloblastoma 272Carcinoma, Non-Small-Cell Lung 227Recurrence 199Sarcoma 184Neoplasm Metastasis 183Melanoma 182Meningioma 177Ependymoma 176Lung Neoplasms 157Lymphoma 134Osteosarcoma 127Meningeal Carcinomatosis 126Neurofibromatosis 1 114Wilms Tumor 111Ovarian Neoplasms 110Diffuse Intrinsic Pontine Glioma 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Rhabdomyosarcoma 101Lymphoma, Non-Hodgkin 96Burkitt Lymphoma 89

Interventions

Temozolomide 1Irinotecan 1Cefixime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Diarrhea × CNS × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡